Know Cancer

or
forgot password

cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project


N/A
N/A
N/A
Open (Enrolling)
Both
Melanoma

Thank you

Trial Information

cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project


Inclusion Criteria:



- melanoma

- white caucasian population

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

c-Kit exons 11, 13, 17 and 18 will be sequenced (direct sequencing and pyrosequencing when possible)

Outcome Description:

c-Kit exons 11, 13, 17 and 18 will be sequenced (direct sequencing and pyrosequencing when possible)

Outcome Time Frame:

Day 1

Safety Issue:

No

Principal Investigator

Marie-Dominique Galibert, PU-PH

Investigator Role:

Principal Investigator

Investigator Affiliation:

Rennes University Hospital

Authority:

France: The Commission nationale de l’informatique et des libertés

Study ID:

LOC/10-16 - KitMel

NCT ID:

NCT01543113

Start Date:

January 2011

Completion Date:

January 2015

Related Keywords:

  • Melanoma
  • melanoma
  • white-caucasian population
  • Melanoma

Name

Location